Microbiome Targeted Drugs Articles & Analysis
3 articles found
Gut microbes are considered "virtual organs" that influence host health and are involved in disease research. The human gut microbiota has a large gene pool, encoding approximately 100-150 times more genes than the human genome, and contains a rich resource of enzymes with the ability to metabolize drugs. The diversity of gut bacteria also affects the mental health of the host. Microbiomes from ...
Symberix co-founder Matt Redinbo also published a research article in PNAS in March 2020 describing microbiota-targeted therapeutics that inhibit gut bacterial β-glucuronidases to enhance anticancer drug efficacy. Symberix, Inc. is a biopharmaceutical company focused on developing the first generation of gut ...
Symberix is developing bacteria-targeted small molecules that prevent the GI toxicity of many common medications, including nonsteroidal anti-inflammatory drugs and irinotecan. “A detailed understanding of which microbiota interact with which drugs, and the mechanisms behind those interactions, could suggest ways to either inhibit or ...